All News
Coal mining is associated with developing RA, but what is it about it?
It's the silica. The more silica and the longer exposed, the more likely. Hopefully, one day, we'll get be able to prevent this...
@UCSFMedicine @UCSFRheum #ACR20 ABST1462 @RheumNow https://t.co/mlZNpJD9iv
David Liew drdavidliew ( View Tweet)
Diet and risk of RA: there's a link, but how healthily do you need to eat?
Benefit keeps on going up to... let's say healthier than your correspondent. No conference burger tonight😐
(benefit goes up to top 11% in study)
Nurses Health Study @jeffsparks #ACR20 ABST1463 @RheumNow https://t.co/4kEOixMQ8e
David Liew drdavidliew ( View Tweet)
Living with #Sjogren #syndrome. Tips for dry mouth management. Dr Papas #ACR20 @RheumNow @ramos_casals https://t.co/uw4NH3yhpn
Sole RetamozoSole ( View Tweet)
Thinking of your last 20 consecutive Axial SpA patients in your clinic, which was the commonest extra-articular manifestation that you encountered? @RheumNow #ACR20 Abstr#1312
Dr. Antoni Chan synovialjoints ( View Tweet)
Abst#1462 shows coal mining and non-coal silica exposure with increased risk of RA with OR ~4. Great study, not a surprise that toxin exposures linked to autoimmunity. #ACR20 @RheumNow. https://t.co/OnwVUfoRCU
Eric Dein ejdein1 ( View Tweet)
Are there distinct groups of axSpA and PsA patients with peripheral arthritis. This study shows heterogeneous patterns of peripheral involvement and overlap in SpA and PsA groups @RheumNow #ACR20 Abstr#1311 https://t.co/2Q5FH6ZrWm
Dr. Antoni Chan synovialjoints ( View Tweet)
Dr Trupin presents further data on link between silica exposure and coal mining in particular with development of incident RA. Duration and intensity of exposure both associated with increased risk. @rheumnow #ACR20 Abstr#1462 https://t.co/5SpqElhlZN
Richard Conway RichardPAConway ( View Tweet)
In this longitudinal observational cohort study, AAU was the most frequent EAM to develop. No impact of gender or disease activity on the development of any EAM @RheumNow #ACR20 Abstr#1312 https://t.co/RTwWoS9sgX
Dr. Antoni Chan synovialjoints ( View Tweet)
Dr. Vibeke Strand previews ACR 2020 highlights, including The Great Debate
https://t.co/Wyeh8pu3ax https://t.co/oCdfywJUoo
Links:
Dr. John Cush RheumNow ( View Tweet)
Detection of inflammatory back pain (IBP) is important for the early diagnosis of Axial SpA. Which IBP criteria do you use in your clinic? @RheumNow #ACR20 Abst#1303
Dr. Antoni Chan synovialjoints ( View Tweet)
Pregnancy outcomes in women with AxSpA
4 prospective cohorts in Europe
328 total pregnancies
Favorable outcomes overall
1⃣3% pre-eclampsia
2⃣6-9% gestational DM
3⃣0-5% preterm birth rates (similar to WHO rate 9% in Eur)
@RheumNow #ACR20 Abs#1498
Robert B Chao, MD doctorRBC ( View Tweet)
COVID-19 changes everything, but our vasculitis patients particularly have had some really difficult decisions to make.
@VasculitisFound @michaelgeorgemd @maferradastrong @petercgrayson @RADoctor @DrPeterMerkel et al
#ACR20 ABST1416 @RheumNow https://t.co/lWXtgSqDqy
David Liew drdavidliew ( View Tweet)
Exploring new mode of action for treatment of AS. In BE AGILE study, Bimekizumab (BKZ) provides further sustained long-term improvements post 48 weeks in key efficacy outcome measures to 96 weeks of treatment @RheumNow #ACR20 Abstr#1364 https://t.co/972AvDNJDq
Dr. Antoni Chan synovialjoints ( View Tweet)
Interim analysis of the RELIANCE registry studying effect of canakinumab (CAN) in 80 patients w/ febrile CAPS. Efficacy of CAN assessed w/ AIDA (inflam index) showing ~70% were in low activity (<9) @ACR20 Abstr#1479 https://t.co/UC2eJbpVLM https://t.co/M71s8gXZY9
Dr. John Cush RheumNow ( View Tweet)
In the current era, would a positive treat-to-target study in AS change your approach to practice?
(TICOSPA trial ABST1444) #ACR20 @RheumNow
David Liew drdavidliew ( View Tweet)
Wanna learn about T2T PsA abstracts from #ACR20? Here are my highlights! @RheumNow https://t.co/0X7FF3rwTz
Dr. Rachel Tate uptoTate ( View Tweet)
Check out my video on T2T in SpA abstracts from #ACR20 @RheumNow https://t.co/ZBvmhWyDHU
Dr. Rachel Tate uptoTate ( View Tweet)
We're getting better at treating vasculitis over time.
In-hospital mortality in pts primarily admitted with vasculitis is got much closer to all-comers 1998-2014 (US NIS). Hopefully with more new meds, we've closed the gap even more since!
@UABRheum #ACR20 ABST1423 @RheumNow https://t.co/kNq8HCjqQ0
David Liew drdavidliew ( View Tweet)
Dr. Crow's #StateoftheArt lecture revealed that BEL may be best used in pts with < 2 years and SLEDAI >10 based on the study from Gatto, M et al from 2020. Does this change how you will use BEL in your practice? #ACR20 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Can hs-troponin and hsCRP predict future major cardiovascular events? Certainly appears so in RA pts (n=636).
To what extent do subclinical dx and inflammation combine to cause future RA CV pain?
PRECISION trial subgroup @ElaineHusniMD @DanielHSolomon #ACR20 ABST1189 @RheumNow https://t.co/ZYTpodatVI
David Liew drdavidliew ( View Tweet)